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Some cancer cells exhibit elevated levels of free fatty
acids (FAs) as well as high levels of b-catenin, a tran-
scriptional co-activator that promotes their growth.
Here, we link these two phenomena by showing
that unsaturated FAs inhibit degradation of b-cate-
nin. Unsaturated FAs bind to the UAS domain of
Fas-associated factor 1 (FAF1), a protein known to
bind b-catenin, accelerating its degradation. FA
binding disrupts the FAF1/b-catenin complex, pre-
venting proteasomal degradation of ubiquitinated
b-catenin. This mechanism for stabilization of b-cat-
enin differs from that of Wnt signaling, which blocks
ubiquitination of b-catenin. In clear cell renal cell car-
cinoma (ccRCC) cells, unsaturated FAs stimulated
cell proliferation through stabilization of b-catenin.
In tissues from biopsies of human ccRCC, elevated
levels of unsaturated FAs correlated with increased
levels of b-catenin. Thus, targeting FAF1 may be an
effective approach to treat cancers that exhibit
elevated FAs and b-catenin.
INTRODUCTION
Cancer cells alter their metabolism to provoke cell proliferation.
One metabolic alteration in cancers is the accumulation of free
fatty acids (FAs), which facilitate cell proliferation through a
mechanism that remains elusive (Nomura et al., 2010). To
pinpoint this mechanism, we studied FA-interacting proteins
that may link free FAs to oncogenic signaling pathways. We pre-
viously identified UAS domains, which contain 160 amino acid
residues, as the motifs that bind unsaturated, but not saturated,
FAs (Kim et al., 2013). This domain polymerizes upon its interac-
tion with unsaturated FAs (Kim et al., 2013). Mammalian cells ex-
press two homologous proteins that contain UAS domains (KimCet al., 2013): Ubxd8, a protein maintaining cellular FA homeosta-
sis by stimulating degradation of Insig-1 (Ye and DeBose-Boyd,
2011), and Fas-associated factor 1 (FAF1), a protein that facili-
tates degradation of b-catenin (Zhang et al., 2011, 2012).
Ubxd8 senses the cellular content of unsaturated FAs to regu-
late degradation of Insig-1, a protein that inhibits transcription of
all genes required for synthesis of FAs (Kim and Ye, 2014; Ye and
DeBose-Boyd, 2011). Through their direct binding to the UAS
domain of Ubxd8, unsaturated FAs cause Ubxd8 to polymerize
and dissociate from Insig-1 so that ubiquitinated Insig-1 cannot
be delivered to proteasomes for degradation (Kim et al., 2013;
Lee et al., 2008, 2010). Like Ubxd8, unsaturated, but not satu-
rated, FAs trigger polymerization of FAF1 upon their interaction
with the UAS domain of the protein (Kim et al., 2013). The func-
tional significance of the interaction between unsaturated FAs
and FAF1 remains unknown.
FAF1 has been reported to be required for degradation of
b-catenin (Zhang et al., 2011, 2012), a transcriptional co-acti-
vator that stimulates expression of genes driving cell prolifera-
tion (Anastas and Moon, 2013). In normal cells, the degradation
of b-catenin is regulated by Wnt signaling: b-catenin is constitu-
tively phosphorylated by the b-catenin destruction complex,
which marks b-catenin for ubiquitination followed by rapid pro-
teasomal degradation (Clevers and Nusse, 2012; Moon et al.,
2002); Wnt signaling inactivates the b-catenin destruction com-
plex, thereby inhibiting phosphorylation of b-catenin and conse-
quently ubiquitination and degradation of the protein (Clevers
and Nusse, 2012; Moon et al., 2002). Mutations that inactivate
proteins required for degradation of b-catenin lead to various
cancers as a result of aberrant accumulation of b-catenin
(Clevers, 2006). However, some cancer cells contain elevated
levels of b-catenin in the absence of these mutations (Barker
and Clevers, 2006). Based on our previous observations with
Ubxd8, we hypothesized that unsaturated FAs may bind to the
UAS domain of FAF1, leading to inactivation of FAF1 and conse-
quently stabilization of b-catenin.
In the current study, we report that unsaturated FAs indeed
inhibit degradation of b-catenin by inactivating FAF1. Weell Reports 13, 495–503, October 20, 2015 ª2015 The Authors 495
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Figure 1. Unsaturated FAs Stabilize b-Cate-
nin through Inactivating FAF1
(A) SRD-13A cells were seeded at 3.5 3 105/
60-mm dish on day 0. On day 1, cells were
depleted of FAs by incubation in medium A sup-
plemented with 5% delipidated fetal calf serum
(DFCS), 5 mg/ml cholesterol, and 1 mM sodium
mevalonate for 14 hr. On day 2, cells were
switched to medium A supplemented with 0.5%
DFCS, 5 mg/ml cholesterol, and 1 mM sodium
mevalonate in the absence or presence of the
indicated FAs (100 mM) or mouse Wnt3a (5 ng/ml).
Following incubation for 6 hr, cells were harvested.
Cell lysate was subjected to SDS-PAGE followed
by immunoblot analysis.
(B) SRD-13A cells seeded as described in (A) were
subjected to pulse-chase analysis as described in
Experimental Procedures. Results are reported as
means ± SE from three independent experiments.
(C)SRD-13Acellswere seededat1.53105/60-mm
dish on day 0. On day 1, cells were transfected with
20mMof the indicatedsiRNA.Ondays3and4, cells
were depleted of FAs and then treated with oleate
as described in (A). Cell lysate was subjected to
SDS-PAGE followed by immunoblot analysis.
(D) Indicated purified proteins were incubated with
oleate added as stock solutions dissolved in
ethanol, subjected to BN-PAGE, and visualized
with Coomassie blue staining.
(E) SRD-13A cells were seeded as described in
(A). On day 1, cells were transfected with 1 mg/dish
pTK-HSV-b-catenin, 0.3 mg/dish pCMV-Myc-FAF1 (WT), or 0.6 mg/dish pCMV-Myc-FAF1 (mutant). Following incubation for 8 hr, cells were depleted of FAs and
then treated with or without oleate on day 2 as described in (A). Cell lysate was subjected to SDS-PAGE followed by immunoblot analysis.demonstrate the clinical significance of these findings by pro-
viding evidence that excess unsaturated FAs stabilize b-catenin
in clear cell renal cell carcinoma (ccRCC), which represents a
majority of kidney cancers (Li and Kaelin, 2011). These results
suggest that compounds blocking the interaction between
FAF1 and unsaturated FAs may be useful in treating cancers
whose proliferation is provoked by unsaturated FA-mediated
stabilization of b-catenin.
RESULTS
Unsaturated FAs Inhibit Degradation of b-Catenin
through Their Interaction with FAF1
We first used SRD-13A cells, a line of mutant CHO cells, to deter-
mine whether unsaturated FAs inhibit degradation of b-catenin.
These cells are auxotrophic for FAs, and consequently, their
content of FAs can be controlled easily by the amount of FAs
added into the culture medium (Rawson et al., 1999). We pre-
incubated the cells in FA-depleted medium and then supple-
mented the medium with various FAs. The effect of these FAs
on levels of b-catenin was determined by immunoblot analysis.
As a positive control, we treated the cells with Wnt3a to block
b-catenin degradation. b-catenin was barely detectable in cells
cultured in the absence of FAs (Figure 1A, lane 1). Addition of
palmitate (C16:0), a saturated FA, did not raise the amount of
b-catenin (Figure 1A, lane 2). However, oleate (C18:1) and other
unsaturated FAs markedly increased the levels of b-catenin (Fig-
ure 1A, lanes 3–8), reaching levels that were comparable to those496 Cell Reports 13, 495–503, October 20, 2015 ª2015 The Authorsin cells treated with Wnt3a (Figure 1A, lane 9). In a pulse-chase
experiment, we demonstrated that oleate increased the amount
of b-catenin by inhibiting degradation of the protein (Figure 1B).
If unsaturated FAs stabilize b-catenin through inactivation of
FAF1, then knockdown of FAF1 should increase the amount of
b-catenin, regardless of the presence of unsaturated FAs. To
test this hypothesis, we transfected SRD-13A cells with a control
siRNA or siRNAs targeting FAF1. Oleate markedly raised the
amount of b-catenin in cells transfected with the control siRNA
(Figure 1C, lanes 1 and 2). Transfection of the cells with two
siRNAs targeting different regions of FAF1 reduced its mRNA
by 70%–80% (Figure S1A) and raised the amount of b-catenin
in cells cultured in the absence of FAs (Figure 1C, lanes 3 and
5). In the absence of FAF1, oleate did not further increase the
amount of b-catenin (Figure 1C, lanes 4 and 6).
Another way to examine the role of FAF1 in FA-regulated
degradation of FAF1 is to generate a mutant version of FAF1
that does not bind unsaturated FAs. Because the mutant
FAF1 may not be inactivated by unsaturated FAs, degradation
of b-catenin should not be inhibited by unsaturated FAs in cells
expressing the mutant FAF1. Our previous structural analysis of
the UAS domain of FAF1, which directly binds unsaturated FAs,
identified a surface patch that is highly enriched in positively
charged amino acid residues (Kim et al., 2013). We demon-
strated that these positively charged residues are conserved
in the UAS domain of Ubxd8 and that substitution of these res-
idues with glutamate abolished the interaction between Ubxd8
and unsaturated FAs (Kim et al., 2013). We thus expressed
IB : Ubiquitin
IB : β-catenin
β-catenin
(-) MG132
(+) MG132
A
β-catenin
FAF1
Input
Pellet
Sup.
FAF1
18:1 20:4
B
p-β-catenin
(S33/37/T41)
β-catenin
Actin
Actin
Wnt3a
CIP : β-catenin 
β-catenin
FAF1
β-catenin
FAF1
C
1 2 3
Oleate
Lane
Wnt3a
1 2 3
Oleate
Lane
IP Antibody
1 2 3
FA
Lane 4
Ubiquitinated
β-catenin
Ubiquitinated
β-catenin
Panel
1
2
3
4
5
Panel
1
2
3
4
5
6
Figure 2. Unsaturated FAs Inhibit Degradation of b-Catenin at a Post-ubiquitination Step
HEK293 cells were seeded at 4.03 105/60-mm dish on day 0. On day 2, cells were incubated in medium B supplemented with 10%DFCS and 1 mMA939572 for
16 hr. On day 3, cells were switched to serum-freemediumB supplemented with 1 mMA939572 and treated with 100 mMoleate, 40 ng/ml humanWnt3a, or 10 mM
MG132 as indicated for 6 hr.
(A) Cell lysate was subjected to SDS-PAGE followed by immunoblot analysis.
(B) b-catenin was immunoprecipitated from lysate of the cells treated with MG132, and the immunoprecipitates were subjected to immunoblot analysis.
(C) Cytosolic fractions of the cells treated with MG132 were subjected to immunoprecipitation with a control antibody (C) or anti-FAF1. Aliquots of the cytosol
fraction before the immunoprecipitation (input) and the pellet and supernatant fractions of the immunoprecipitation were loaded at a ratio of 1:10:1 on SDS-PAGE
followed by immunoblot analysis.and purified a mutant variant of the UAS domain of FAF1 (FAF1
325–491) with the corresponding amino acid substitutions
(K368E, R370E, R372E, K373E, K457E, and R458E). The inter-
action between oleate and the FAF1 UAS domain was detected
by oleate-induced polymerization of the protein as revealed by
blue native PAGE (BN-PAGE) (Kim et al., 2013; Lee et al.,
2010). Oleate induced the polymerization of the wild-type UAS
domain (Figure 1D, lanes 1–4), but not the mutant UAS domain
(Figure 1D, lanes 5–8). This observation indicates that the
mutant UAS domain of FAF1 does not interact with unsaturated
FAs. Next, we transfected SRD-13A cells with plasmids encod-
ing b-catenin and wild-type FAF1 or mutant FAF1 with the mu-
tations in the UAS domain described above. When b-catenin
was overexpressed by transfection, the protein was present
even in the absence of FAs and there was no further stabilization
by oleate (Figure 1E, lanes 2 and 3). Cotransfection of wild-type
FAF1 reduced the amount of b-catenin in FA-depleted cells, and
this reduction was blocked by oleate (Figure 1E, lanes 4 and 5).
This result suggests that FAF1 is a limiting factor for degradation
of b-catenin when it is overexpressed. Cotransfection with a
plasmid encoding mutant FAF1 reduced the amount of b-cate-
nin, but this reduction was no longer reversed by addition of
oleate (Figure 1E, lanes 6 and 7). Collectively, these findings
suggest that FAF1 accelerates b-catenin degradation and that
the interaction between unsaturated FAs and the UAS domain
of FAF1 is required for these FAs to inhibit degradation of
b-catenin.
The effect of unsaturated FAs on degradation of b-catenin is
not restricted to SRD-13A cells. Unsaturated, but not saturated
FAs, also stabilized the protein in HEK293 cells that are not
auxotrophic for FAs (Figure S1B). A difference between this
experiment and that performed in SRD-13A cells is that, in addi-
tion to incubating cells in FA-free medium, we treated HEK293
cells with A939572, an inhibitor of stearoyl-CoA desaturase-1
(SCD1), which catalyzes the rate-limiting step in biosynthesisCof unsaturated FAs (Paton andNtambi, 2010), to deplete the cells
of unsaturated FAs.
Unsaturated FAs Stabilize b-Catenin through a
Mechanism Different from Wnt Signaling
Because HEK293 cells have been used to study Wnt-regulated
degradation of b-catenin (Li et al., 2012), we used these cells
to compare unsaturated FA versus Wnt-mediated stabilization
of b-catenin. We first determined the effect of unsaturated FAs
on phosphorylation of b-catenin. Both oleate and Wnt3a in-
creased the amount of b-catenin in HEK293 cells cultured in
FA-depleted medium (Figure 2A, panel 4). To analyze phosphor-
ylation of b-catenin, we treated the cells with a proteasome in-
hibitor MG132 to prevent the degradation of the phosphorylated
protein (Figure 2A, panel 2). Whereas Wnt3a inhibited phosphor-
ylation of b-catenin (Figure 2A, panel 1, lane 3), oleate increased
the amount of phosphorylated b-catenin (Figure 2A, panel 1,
lane 2). To determine the impact of these treatments on ubiquiti-
nation of b-catenin, we immunoprecipitated b-catenin from ly-
sates of cells treated with MG132 and measured ubiquitinated
b-catenin as detected by high-molecular-weight smears in
immunoblot analysis of the immunoprecipitates with anti-b-cat-
enin and anti-ubiquitin. Ubiquitinated b-catenin was observed in
untreated cells (Figure 2B, lane 1). In contrast to Wnt3a, which
reduced the level of ubiquitinated b-catenin (Figure 2B, lane 3),
oleate increased the amount of ubiquitinated b-catenin (Fig-
ure 2B, lane 2). The results of Wnt treatment are consistent
with previous observations that Wnt inhibits phosphorylation
and ubiquitination of b-catenin. In contrast, unsaturated FAs pre-
vent the degradation of ubiquitinated b-catenin.
Next, we investigated whether unsaturated FAs disrupted
the FAF1/b-catenin complex that is known to be required for
degradation of b-catenin (Zhang et al., 2012). For this purpose,
we treated HEK293 cells with MG132 to prevent proteasomal
degradation of b-catenin. We immunoprecipitated FAF1 andell Reports 13, 495–503, October 20, 2015 ª2015 The Authors 497
determined the amount of b-catenin that was co-precipitated.
b-catenin was co-immunoprecipitated with FAF1 in FA-depleted
cells (Figure 2C, panel 4, lane 2), but not in cells treated with
oleate or arachidonate (C20:4), another unsaturated FA (Fig-
ure 2C, panel 4, lanes 3 and 4).
Stabilization of b-Catenin by Unsaturated FAs Is
Required for Proliferation of ccRCC Cells
ccRCC is characterized by excess lipid accumulation, owing to
increased synthesis of FAs and cholesterol (Drabkin and Gem-
mill, 2010; Li and Kaelin, 2011). The increased synthesis of unsat-
urated FAs appears to be important for proliferation of ccRCC
cells, as growth of mouse xenograft tumors was inhibited by
treatment with A939572, an inhibitor of SCD1 required for syn-
thesis of unsaturated FAs (von Roemeling et al., 2013). A recent
study also reported increased b-catenin levels as a predictor of
poor clinical outcomes in ccRCC patients (Krabbe et al., 2014).
We thus hypothesized that accumulation of excess unsaturated
FAs in ccRCC tumor cells may promote their proliferation
through stabilization of b-catenin.
To test this hypothesis, we studied the impact of unsaturated
FAs on b-catenin levels in the ccRCC cell line SW156. These cells
contain much more triglyceride, cholesterol, and free unsatu-
rated FAs than HEK293 cells (Figures S2A–S2C). Unlike SRD-
13A cells, in which b-catenin is not associated with membranes,
in SW156 cells, a significant fraction of b-catenin is membrane-
associated (Figure S2D). This pool of b-catenin is known to be
required for cell adhesion, but not for stimulation of cell prolifer-
ation, and it is not subjected to rapid degradation (Fagotto,
2013). Therefore, we assessed the effect of FAs on stabilization
of cytosolic b-catenin. As observed in SRD-13A cells, we found
that addition of unsaturated, but not saturated, FAs stabilized
cytosolic b-catenin in SW156 cells (Figure 3A). We then deter-
mined the effect of unsaturated FAs on expression of cyclin
D1, a target gene of b-catenin that drives cell proliferation (Shtut-
man et al., 1999; Tetsu andMcCormick, 1999).We found that un-
saturated, but not saturated, FAs caused a marked increase in
cyclin D1 mRNA expression (Figure 3B). To confirm that the
increased expression of cyclin D1was caused by elevated b-cat-
enin, we treated the cells with NCX4040, which inhibits the tran-
scriptional co-activating activity of b-catenin (Nath et al., 2003).
Treatment with NCX4040 completely abolished oleate-induced
expression of cyclin D1 mRNA (Figure 3C).
Next, we analyzed the effect of unsaturated FA-mediated sta-
bilization of b-catenin on cell proliferation. We incubated SW156
cells in FA-depleted medium in the absence or presence of the
SCD1 inhibitor A939572 and then treated the cells with various
concentrations of oleate. In the absence of exogenous oleate,
a small amount of b-catenin was detected in cells incubated in
the absence of A939572 (Figure 3D, lane 1). The protein disap-
peared upon treatment with A939572 (Figure 3D, lane 2). In par-
allel with the amount of b-catenin, the cells proliferated in the
absence, but not the presence, of A939572 (Figure 3E, oleate
at 0 mM). Addition of exogenous oleate increased the amount
of b-catenin in cells treated with or without A939572 (Figure 3D,
lanes 3–12). At 20 mM, the added oleate raised the amount of
b-catenin in cells treated with A939572 to the same level as
that in cells incubated in the absence of the inhibitor (Figure 3D,498 Cell Reports 13, 495–503, October 20, 2015 ª2015 The Authorslanes 11 and 12). In parallel with the amount of b-catenin, exog-
enous oleate increased the proliferation rate of the cells treated
with or without A939572 (Figure 3E). At 20 mM of added oleate,
cell proliferation rate was the same in the presence or absence
of A939572 (Figure 3E). To make a more-direct comparison,
we used mass spectroscopy to measure the amount of free un-
saturated FAs in cells subjected to all of these treatments. We
plotted the amount of b-catenin and the rate of cell growth
against the content of unsaturated FAs. The amount of b-catenin
(red) and the rate of cell growth (blue) were positively correlated
with the intracellular content of unsaturated FAs, and the linear
fitting of both data sets was almost superimposable (Figure 3F).
These results strongly suggest that unsaturated FA-mediated
stabilization of b-catenin is responsible for cell proliferation.
In addition to SW156 cells, we observed accumulation of lipids
including unsaturated FAs in 786-O cells, another line of ccRCC
cells (Figures S2A–S2C). In these cells, unsaturated, but not
saturated, FAs also stabilized b-catenin (Figure S2E) in a FAF1-
dependent manner, as b-catenin was stabilized regardless of
the presence of the FAs in the cells in which FAF1 was knocked
down by the transfected siRNA (Figure S2F). Similar to SW156
cells, the stabilization of b-catenin in 786-O cells was correlated
to cell proliferation (Figure S2G).
Excess Unsaturated FAs Increase Oncogenic Activity of
b-Catenin in Specimens of ccRCC Tumors
To further substantiate the clinical relevance of our findings,
we analyzed the correlation between unsaturated FAs and the
intracellular distribution of b-catenin in biopsies exercised
from patients with ccRCC. We determined the subcellular local-
ization of b-catenin in 25 tumors by immunohistochemistry.
Whereas most tumor cells showed b-catenin staining on plasma
membranes (Figure 4A), a few of them, for example tumor no.
22383, had intracellular staining of the protein (Figure 4B). The
strong intracellular staining of b-catenin (>60%) was only
observed in grade 4 ccRCC cells, which constitute the most
aggressive form of the tumors (Figure 4C, red bars; no. 21886,
no. 22383, no. 24152, and no. 21470). We then used mass spec-
troscopy to measure free unsaturated FAs in all of the 25 tumors
and found that only these four tumors accumulated higher levels
of the FAs in comparison to their benign controls (Figure 4C, blue
bars; no. 21886, no. 22383, no. 24152, and no. 21470). Other tu-
mors had no or low intracellular staining of b-catenin (<35%; Fig-
ure 4C, red bars), and most of them contained lower levels of
unsaturated FAs compared to their benign controls (Figure 4C,
blue bars). The probability of the correlation between increased
intracellular distribution of b-catenin and increased levels of un-
saturated FAs in tumor cells occurring by chance is 105 as
determined by Pearson analysis. These results suggest that, in
ccRCC, increased levels of unsaturated FAs stabilize intracel-
lular b-catenin.
We then performed gene expression analyses using RNA-seq
data from 532 human ccRCC samples generated by The Cancer
Genome Atlas project. Because SCD1 catalyzes the rate-limiting
step in the biosynthesis of unsaturated FAs, tumors with higher
expression of the gene are expected to produce more unsatu-
rated FAs. Thus, if unsaturated FAs stabilize b-catenin, tumors
with higher expression of SCD1 should also express higher
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Figure 3. Excess Unsaturated FAs Promote Proliferation of SW156 through Stabilization of b-Catenin
(A) SW156 cells were seeded at 3.53 105/60-mm dish on day 0. On day 1, cells were depleted of FAs by incubation in medium C supplemented with 10% DFCS
and 1 mM A939572 for 24 hr. On day 2, cells were switched to serum-free medium C supplemented with 1 mM A939572 and treated with 100 mM of the indicated
FA for 6 hr. Cytosolic fractions were subjected to SDS-PAGE followed by immunoblot analysis.
(B and C) SW156 cells were seeded on day 0 and depleted of FAs on day 1 as described in (A). On day 2, cells were switched to serum-free medium C sup-
plemented with 1 mMA939572 and treated with 100 mMof the indicated FA in the absence or presence of 10 mMNCX4040 for 9 hr. The amount of cyclin D1mRNA
was determined by qRT-PCR with the value in untreated FA-depleted cells set at 1. Results are reported as means ± SE from three independent experiments.
(D) SW156 cells were seeded at 1.0 3 105/60-mm dish on day 0. On day 1, cells were switched to medium C supplemented with 10% DFCS and the indicated
concentration of oleate in the absence or presence of 1 mM A939572. On day 3, after incubation for 60 hr, cytosolic fractions of the cells were subjected to
immunoblot analysis.
(E) SW156 cells were seeded at 800/well in a 96-well plate on day 0. On day 1, cell number was determined in some wells of the cells. The rest of the cells were
treated the same as described in (D). On day 3, after incubation for 60 hr, the cell number in each well was determined, and the percentage increase in the cell
number compared to that in day 1 was presented. Results are reported as means ± SE from three independent experiments.
(F) Densitometry quantification of b-catenin protein in (D) (red) and relative cell growth observed in (E) (blue) were plotted against intracellular concentration of
unsaturated FAs measured by mass spectroscopy in all of the treatment conditions in (D) and (E).levels of b-catenin target genes.We identified 1,024 genes as the
top 5% of genes whose expression is positively correlated with
SCD1 expression (Table S1). When we analyzed these genes
for enrichment in functional annotation categories, we foundCenrichment in biological processes that are relevant to cell prolif-
eration and cancer signaling (Figure S3). When we analyzed
transcription factor motifs in the promoter regions of these
genes, we found enrichment for a LEF1 motif, which is typicalell Reports 13, 495–503, October 20, 2015 ª2015 The Authors 499
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Figure 4. Increased Levels of Unsaturated FAs Are Correlated to Elevated Levels of Intracellular b-Catenin in ccRCC Patient Specimens
(A and B) Immunohistochemistry staining of b-catenin in the indicated ccRCC patient specimen was performed as described in Experimental Procedures.
(C) The relative amount of unsaturated FAs in tumors was measured through mass spectroscopy analysis, with the value in their benign controls set at 1 (blue
bars). The relative intracellular staining of b-catenin in ccRCC patient specimens was determined as described in Experimental Procedures (red bars). The
pathological grade of the tumors is indicated. The sample numbers for the tumors with higher levels of intracellular staining of b-catenin and unsaturated FAs are
highlighted in brown. The results are reported as means ± SE from three independent measurements. Paired Student’s t test was performed to determine the
statistical significance of the increase in the amount of unsaturated fatty acids in the highlighted tumors compared to their benign controls: *p = 0.02; **p < 0.01.
(D) Venn diagram displaying overlap in putative target genes of b-catenin and genes whose expression is positively correlated with SCD1 expression. Adjusted
p = 4.3 3 1022.for the gene-specific transcription factors that use b-catenin as a
co-activator (Arce et al., 2006; Schuijers et al., 2014). The LEF1
motif was the second most significantly enriched motif in pro-
moters for genes whose expression is positively correlated
with SCD1 expression (adjusted p = 4.3e22). Out of the 1,939
human genes with this motif in their promoter regions, 126 genes
were found in the set of 1,024 geneswhose expression was posi-
tively correlated with SCD1 expression (Figure 4D; Table S1).
This number is 2.74 times higher than expected from random
overlap between the two gene sets. These analyses suggest
that the potential target genes of b-catenin are overexpressed
in ccRCC cells that express high levels of SCD1 mRNA.
DISCUSSION
The current study supports a model shown in Figure 5, illus-
trating how unsaturated FAs and Wnt independently inhibit
proteasomal degradation of b-catenin. Previous studies have
demonstrated that b-catenin is constitutively phosphorylated
by the b-catenin destruction complex, which marks b-catenin500 Cell Reports 13, 495–503, October 20, 2015 ª2015 The Authorsfor ubiquitination by a b-Trcp-containing E3 ubiquitin ligase com-
plex (Clevers and Nusse, 2012; Moon et al., 2002). The ubiquiti-
nated b-catenin may then be targeted by FAF1 to proteasomes
for degradation (Figure 5, middle panel). Activation of Wnt
signaling recruits the destruction complex to plasma mem-
branes, thereby preventing phosphorylation and ubiquitination
of b-catenin and resulting in stabilization of the protein (Clevers
and Nusse, 2012; Moon et al., 2002; Figure 5, left panel). In
contrast to Wnt signaling, unsaturated FAs do not affect phos-
phorylation or ubiquitination of b-catenin. Instead, the FAs
disrupt the FAF1/b-catenin complex by triggering polymerization
of FAF1. Consequently, ubiquitinated b-catenin is not targeted to
proteasomes for degradation, thereby stabilizing b-catenin (Fig-
ure 5, right panel).
Exactly how FAF1 targets ubiquitinated b-catenin to protea-
somes for degradation remains unclear. A previous study re-
ported that recognition of ubiquitinated Insig-1 by proteasomes
required recruitment of p97 to Insig-1, a reaction mediated by
Ubxd8 that is a homolog of FAF1 (Ikeda et al., 2009). Inasmuch
as FAF1 also binds p97 (Ewens et al., 2014), the mechanism
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Figure 5. Model Illustrating that Unsaturated FAs and Wnt Stabilize b-Catenin via Different Mechanisms
In the absence of Wnt and unsaturated fatty acids, b-catenin is phosphorylated by the b-catenin destruction complex, a reaction marking the protein for
ubiquitination followed by rapid degradation by proteasomes. Activation of Wnt signaling stabilizes b-catenin by inhibiting phosphorylation and ubiquitination of
the protein through recruiting the destruction complex to plasmamembranes. In contrast toWnt, unsaturated FAs do not affect phosphorylation or ubiquitination
of b-catenin. Instead, the FAs trigger polymerization of FAF1, causing dissociation of the protein from b-catenin. As a result, b-catenin is stabilized as ubiq-
uitinated b-catenin is not delivered to proteasomes for degradation. In the absence of proteasomal degradation, polyubiquitin chains on b-catenin may be
cleaved off by reactions catalyzed by deubiquitinating enzymes (DUB), allowing b-catenin to activate its target genes in nucleus.through which FAF1 facilitates degradation of ubiquitinated
b-catenin may be similar to that through which Ubxd8 stimulates
degradation of ubiquitinated Insig-1.
The strongest evidence indicating that unsaturated FAs inhibit
degradation of b-catenin through a mechanism different from
Wnt signaling comes from the observations that, in contrast
to activation of Wnt signaling, these FAs do not affect phosphor-
ylation or ubiquitination of b-catenin. This mechanism is different
from an earlier report showing the correlation between FA
synthesis and stabilization of b-catenin: in that study, FA syn-
thesis was shown to be required for palmitoylation of Wnt
(Fiorentino et al., 2008), a post-translational modification of
Wnt critical for its signaling function. Instead of inhibiting ubiqui-
tination of b-catenin, unsaturated FAs prevent degradation of
ubiquitinated b-catenin. In the absence of proteasomal degrada-
tion, the polyubiquitin chains on b-catenin may be removed from
the protein by deubiquitinating enzymes. The presence of the
strong deubiquitination activity in mammalian cells may explain
why the effect of unsaturated FAs on stabilization of nonubiqui-
tinated b-catenin is more pronounced than that of ubiquitinated
b-catenin.
The current study establishes that accumulation of unsatu-
rated FAs can act as an oncogenic mechanism to increase
b-catenin levels, which is different from the well-established
mechanism caused by genetic inactivation of proteins in Wnt
signaling. We determined that accumulation of excess unsatu-
rated FAs was responsible for stabilization of b-catenin in
some ccRCC tumors. We observed that aberrant stabilization
of b-catenin in several grade 4 ccRCC tumors, the most-aggres-
sive form of the cancer, was correlated to their increased levels
of unsaturated FAs. Through bioinformatics analysis, we showed
that the potential target genes of b-catenin were overexpressed
in ccRCC cells that express high levels of SCD1 mRNA, whichCencodes the enzyme catalyzing the rate-liming step in synthesis
of unsaturated FAs. These genes include Cyclin D1, met proto-
oncogene, andmatrix metallopeptidase 14 that have been previ-
ously determined to be the target gene of b-catenin (Herbst et al.,
2014; Shtutman et al., 1999; Tetsu and McCormick, 1999).
Among these genes, we showed that Cyclin D1 was activated
by b-catenin in ccRCC cells. In addition to ccRCC, it will be inter-
esting to determine whether accumulation of unsaturated FAs is
also responsible for aberrant stabilization of b-catenin in other
cancers that do not contain genetic mutations affecting the
Wnt pathway.
Our finding provides mechanistic insights into the observa-
tions that accumulation of free FAs facilitates development and
progression of certain cancers (Nomura et al., 2010, 2011).
Similar to ccRCC, these cancer cells may acquire FAs through
enhancing their endogenous synthesis. They may also obtain
FAs from plasma, which may explain why obesity, a condition
associated with increased amount of free FAs in circulation, is
a risk factor for cancer development (Park et al., 2014).
The current study further demonstrates the critical roles
played by the UAS domain in transmitting signals elicited by un-
saturated FAs. We have shown previously that binding of unsat-
urated FAs to the UAS domain of Ubxd8 is crucial for feedback
inhibition of FA synthesis through inhibiting degradation of In-
sig-1 (Ye and DeBose-Boyd, 2011). In the current study, we
show that binding of unsaturated FAs to the UAS domain of
FAF1 is required for these FAs to inhibit degradation of b-catenin.
These results suggest that compounds blocking the interaction
between unsaturated FAs and the UAS domain of FAF1 should
destabilize b-catenin. It will be interesting to determine whether
the UAS domain of FAF1 could be targeted by drugs to treat can-
cers whose proliferation is dependent on unsaturated FA-medi-
ated stabilization of b-catenin.ell Reports 13, 495–503, October 20, 2015 ª2015 The Authors 501
EXPERIMENTAL PROCEDURES
Measurement of Lipids
Free FAs from approximately 0.5million cells or 5mg of tumors were quantified
using gas chromatography-electron capture negative ionization-mass spec-
trometry as previously described (Morselli et al., 2014; Quehenberger et al.,
2011). Triglycerides and free cholesterol were isolated from lipid extracts
using Biotage isolute NH2 SPE cartridges according to the instruction of
the manufacturer. The amount of triglycerides was determined by the
amount of free FAs released from triglycerides following saponification as
previously described (Quehenberger et al., 2011). The amount of cholesterol
was determined by Infinity Cholesterol according to the instruction of the
manufacturer.
Immunohistochemistry
Immunohistochemistry staining for b-catenin in ccRCC tumors was performed
exactly as previously described (Krabbe et al., 2014). Intensity of intracellular
(Ii) and membrane staining (Im) of b-catenin as well as percentage of the
cells showing intracellular (Pi) and membrane staining (Pm) of the protein
was determined. Relative intracellular staining of b-catenin was calculated
as Ii 3 Pi/(Ii 3 Pi + Im 3 Pm) 3 100%.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.09.010.
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